CDC Town Hall Meeting on Laboratory Biosafety – Use of Laboratory Instruments, June 24, 2022
CDC’s Division of Laboratory Systems will host a town hall in collaboration with clinical and public health laboratory partners and instrument manufacturers. The purpose of this meeting is to provide an overview and discussion on laboratory biosafety when using laboratory instruments to test human and biologic specimens. The publication Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future discussed critical gaps in clinical laboratory biosafety, including issues related to the use and disinfection of laboratory instruments.
Clinical specimens might contain infectious agents that could cause disease in laboratory professionals if exposure takes place during testing, including during the use of laboratory instruments. During the Ebola outbreak of 2014, real and perceived concerns about instrument safety emerged and led laboratories to delay their testing – or refuse to test altogether – due to concerns about exposure to the Ebola virus. These concerns resulted in patient safety issues due to a delay in or lack of testing availability. When testing could be made available, it often resulted in additional biosafety measures, including additional personal protective equipment (PPE), instrument shields, workflow alterations, and adoption of dedicated point-of-care instrumentation. This town hall collaboration is designed to foster mutual understanding of the multiple perspectives on biosafety issues with laboratory instrumentation revealed during the Ebola outbreak. The goal is to co-develop practical solutions to address issues or gaps and improve pandemic preparedness.
The meeting will be held virtually on June 24, 2022, from 10:00 a.m. to 3:30 p.m., EDT. The agenda will include presentations and discussions on four topic areas:
- Medical device design and incorporation of safety and biosafety
- Perceived risks to laboratory personnel and impact on testing
- Independent assessment of risks and instrument design
- A discussion of potential areas for improvement
There will be prepared presentations, discussions among presenters and panelists, and a period for questions and written public comments. Agenda items are subject to change.
Please click the link below to join the webinar:
Or One tap mobile :
US: +16692545252,,1607624738#,,,,*78880454# or +16468287666,,1607624738#,,,,*78880454#
Dial(for higher quality, dial a number based on your current location):
US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
Webinar ID: 160 762 4738
International numbers available: https://cdc.zoomgov.com/u/abK8yKlS07
Or an H.323/SIP room system:
H.323: 22.214.171.124 (US West) or 126.96.36.199 (US East)
Meeting ID: 160 762 4738
You are invited to participate by submitting written comments. CDC will carefully consider all comments submitted.
Comments, including attachments and other supporting materials will be posted on the CDC Safe Labs website at https://www.cdc.gov/safelabs/. Email written comments to email@example.com. All written comments must be received on or before June 17, 2022.
Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display on CDC’s website.
CDC will review all submissions and may choose to redact or withhold submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign.
Attendees may submit additional comments or questions after the meeting to firstname.lastname@example.org.